Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

Splenectomy is an effective therapy for steroid-refractory or dependent immune
thrombocytopenia (ITP). With the advent of medical alternatives such as rituximab and …

Immune thrombocytopenia (ITP) is a common bleeding disorder caused primarily by
autoantibodies against platelet GPIIbIIIa and/or the GPIb complex. Current theory suggests …

Immune thrombocytopenia (ITP) is a rare disorder and meets the criteria for an orphan
disease. Expertise in the management of these patients is not widely spread. The following …

The paradigm for managing primary immune thrombocytopenia (ITP) in adults has changed
with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options for …

Recent evidence of distinct ITP pathophysiology has opened new exploratory avenues for
disease management. We will discuss the utility of investigations into these mechanisms of …

The management of patients with immune thrombocytopenia (ITP) is rapidly evolving. Over
the last 15 years, a number of novel treatments have improved practice, with many steroid …

Primary immune thrombocytopenia is an autoimmune disorder of unknown cause affecting
both children and adults. The low peripheral blood platelet count is caused by premature …

The treatment of choice in steroid-resistant immune thrombocytopenia is still controversial
due to the recent advent of new drugs (anti-CD20 antibodies and thrombopoietin mimetics) …

In primary chronic immune thrombocytopenia, long‐term response to splenectomy, with 60%
of patients enjoying a treatment‐free life, is higher when compared with rituximab and …